These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37553501)

  • 1. Immunotherapy responses of patients with metastatic melanoma are linked to IL-17 signaling.
    Nat Cancer; 2023 Sep; 4(9):1224-1225. PubMed ID: 37553501
    [No Abstract]   [Full Text] [Related]  

  • 2. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report.
    Clark JI; Bufalino S; Singh S; Borys E
    J Immunother Cancer; 2018 Jun; 6(1):53. PubMed ID: 29898784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic Melanoma.
    Davick JJ; Gaughan E; Barry M; Gru AA
    Am J Dermatopathol; 2018 Jan; 40(1):60-63. PubMed ID: 28719434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.
    Rochlitz C; Dreno B; Jantscheff P; Cavalli F; Squiban P; Acres B; Baudin M; Escudier B; Heinzerling L; Morant R; Herrmann R; Dietrich PY; Dummer R
    Cancer Gene Ther; 2002 Mar; 9(3):289-95. PubMed ID: 11896446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma.
    Damodaran S; Mrozek E; Liebner D; Kendra K
    J Natl Compr Canc Netw; 2014 Dec; 12(12):1666-70; quiz 1670. PubMed ID: 25505207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
    Marabondo S; Kaufman HL
    Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients.
    Bright R; Coventry BJ; Eardley-Harris N; Briggs N
    J Immunother; 2017 Jan; 40(1):21-30. PubMed ID: 27875387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.
    Bastholt L; Svane IM; Bjerregaard JK; Herrstedt J; Hróbjartsson A; Schmidt H
    Eur J Cancer; 2019 Jul; 115():61-67. PubMed ID: 31108244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
    Kruit WH; Goey SH; Calabresi F; Lindemann A; Stahel RA; Poliwoda H; Osterwalder B; Stoter G
    Br J Cancer; 1995 Jun; 71(6):1319-21. PubMed ID: 7779731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 therapy of cancer-clinical perspectives.
    Majidpoor J; Mortezaee K
    Int Immunopharmacol; 2021 Sep; 98():107836. PubMed ID: 34218217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.
    Agarwala S
    Am J Clin Dermatol; 2003; 4(5):333-46. PubMed ID: 12688838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?
    Hurst R; White DE; Heiss J; Lee DS; Rosenberg SA; Schwartzentruber DJ
    J Immunother; 1999 Jul; 22(4):356-62. PubMed ID: 10404437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new approach in the treatment of metastatic melanoma: adoptive immunotherapy using lymphokine-activated killer cells and interleukin 2].
    Keilholz U; Welters H; Dummer R; Tilgen W; Hunstein W
    Hautarzt; 1988 Jun; 39(6):378-81. PubMed ID: 3261288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
    Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
    Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene.
    Stingl G; Brŏcker EB; Mertelsmann R; Wolff K; Schreiber S; Kămpgen E; Schneeberger A; Dummer W; Brennscheid U; Veelken H; Birnstiel ML; Zatloukal K; Schmidt W; Maass G; Wagner E; Baschle M; Giese M; Kempe ER; Weber HA; Voigt T
    Hum Gene Ther; 1996 Mar; 7(4):551-63. PubMed ID: 8800750
    [No Abstract]   [Full Text] [Related]  

  • 20. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
    Clemons-Miller AR; Chatta GS; Hutchins L; Angtuaco EJ; Ravaggi A; Santin AD; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):917s-924s. PubMed ID: 11300492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.